Mankind Pharma outlook 2026: Jefferies sees 19% upside

Why Mankind Pharma is back in focus

Brokerage commentary on Indian pharma is increasingly centred on two near-term themes: a tougher global profit pool in the first half of 2026, and a domestic market that is still growing steadily. Within that frame, Jefferies has maintained a Buy view on Mankind Pharma, calling it a preferred domestic pick even after a setback in the September quarter. The brokerage’s stance is built on expectations of a recovery as the company moves past a nine-month period of core business reorganisation and integration of Bharat Serums & Vaccines (BSV). Mankind’s positioning also intersects with the approaching GLP-1 (semaglutide) opportunity in India, which several brokers expect to trigger competitive action from March to April.

Jefferies rating, target price and implied upside

Jefferies has reiterated its Buy rating on Mankind Pharma and lifted its price target to Rs 3,000 from Rs 2,870. The new target implies an upside of 19%, according to the brokerage note cited in the update. Jefferies also flagged that its Rs 3,000 target is the third-highest among 16 analysts covering the stock, with LSEG data showing a median price target of Rs 2,730. In a downside scenario where recovery in the base business is delayed and BSV synergies do not come through, Jefferies estimates the downside is less than 10%. The brokerage’s base-case return expectation is 19%, with a bull-case outcome of over 30%, based on its framework.

What the latest quarterly numbers show

In the quarter ended March 31, Mankind Pharma’s consolidated net earnings from ongoing operations rose to Rs 554 crore, compared with Rs 425 crore a year earlier. Operational revenue increased by about 12% to Rs 3,443 crore. These numbers provide context to the broader discussion around domestic momentum, even as brokerages debate the near-term impact of portfolio shifts, cost structures, and competitive intensity. Jefferies has described Mankind as a best-in-class franchise going through a temporary rough patch, with near-term margins expected to be at the lower end of guidance.

Domestic formulations and March growth signals

Motilal Oswal said Mankind Pharma’s domestic formulations business is in a “revival phase.” It highlighted 11.5% growth in March for the company’s domestic formulations segment, ahead of the Indian pharmaceutical market growth rate of 10.6% for the same period. The growth was attributed to strong performance in chronic therapies, including cardiac and anti-diabetic treatments. This matters because broker commentary for 2026 expects domestic pharma growth to remain steady, with market growth projected at high single digits and largely price-led amid weak volumes.

Semaglutide plans: Samakind and positioning

Mankind Pharma is launching Samakind, its generic version of semaglutide, on Day 1, using its network across cities and smaller towns. The company is positioning the drug across diabetes, obesity, heart care and gynaecology, as described in the report. Jefferies has separately estimated that with the right pricing and uptake, the domestic market could eventually reach $1 billion. The timing of India’s GLP-1 launches from March to April is described as a key swing factor for the sector, with expectations of intense competition once launches start.

Pharma in 2026: “a tale of two halves”

Jefferies characterises 2026 as “a tale of two halves” for pharma. The first half is expected to be subdued, especially for companies benefiting from the high-margin Revlimid generic opportunity, where competition is expected to intensify from February. Dr. Reddy’s is seen as the most exposed, followed by Zydus and Cipla, while Sun Pharma is considered the least affected due to lower dependence on such products. Jefferies expects these players to return to double-digit earnings growth in the second half, with US price erosion staying in the mid-single-digit range.

Consolidation, growth outlook and where Mankind fits

Jefferies expects consolidation in the sector to continue and identifies Mankind as its preferred domestic pick. Across FY26 to FY28, Jefferies forecasts double-digit revenue growth for the sector, led by Biocon at 14% with upcoming launches. Ajanta Pharma and Mankind are expected to deliver 12% growth, while Sun Pharma, Torrent, JB Pharma and Emcure are each seen expanding at around 11%. Zydus and Alkem are pegged at 10% CAGR. By contrast, companies losing high-margin exclusivity in the US are expected to see slower growth, including Cipla at 8.5%, and Lupin and Dr. Reddy’s at around 6%.

What Jefferies expects from the BSV integration and margins

Jefferies believes Mankind is poised for recovery in the second half of fiscal 2026 as benefits of restructuring and BSV integration begin to materialise. It expects operating expenses to moderate, supporting margin recovery. The synergies from the BSV acquisition are expected to start reflecting in the 26% Ebitda margin guidance for FY26. Jefferies has also lowered its FY26 to FY27 Ebitda estimates by 2% to 5% to account for a slower-than-expected recovery and values the stock at 28 times September 2027 estimated EV/Ebitda.

Key numbers and forecasts at a glance

Market impact and why investors are tracking these triggers

The immediate market focus is on whether Mankind’s domestic growth normalises in the second half of FY26, as Jefferies expects India Rx growth to stabilise later in the fiscal. The other key trigger is the GLP-1 launch window in March to April, where Samakind’s Day 1 entry highlights the push into chronic categories. Separately, the sector backdrop of eroding high-margin exclusivities and regulatory overhangs adds sensitivity to near-term earnings for US-exposed names, even as domestic demand is expected to provide stability. Jefferies’ framework effectively positions Mankind as a domestic-led recovery play within a year where outcomes may differ sharply between the first and second halves.

Conclusion

Jefferies’ Buy call on Mankind Pharma rests on a second-half FY26 recovery, moderation in operating expenses, and improving benefits from the BSV integration, alongside a sharper domestic product cycle driven by semaglutide launches. Near-term attention is likely to remain on how margins track against the FY26 Ebitda guidance and how quickly India Rx growth normalises in the second half of the fiscal.